ResMed director sells 970 shares at $234.73

ResMed director Peter C. Farrell sold 970 shares under a pre-arranged Rule 10b5-1 trading plan and now reports holding 51,803 shares directly.

Rhea-AI Filing Summary

RESMED INC (RMD) director Peter C. Farrell reported selling 970 shares of ResMed common stock on September 2, 2026 in an open-market or private transaction at $234.73 per share. The sale was conducted under a Rule 10b5-1 trading plan adopted on August 12, 2025, and he reported 51,803 shares of direct ownership following the transaction.

Insider Trade Summary 10b5-1

Net Seller: 970 shares

Net Sell 1 txn

Insider FARRELL PETER C

Role Director

Sold 970 shs ($228K)

Type	Security	Shares	Price	Value
Sale	ResMed Common Stock F1	970	$234.73	$228K

Holdings After Transaction: ResMed Common Stock — 51,803 shares (Direct)

Footnotes (1)

1. F1. The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025.

Key Figures

Shares sold: 970 shares Sale price per share: $234.73 per share Shares held after transaction: 51,803 shares +2 more

5 metrics

Shares sold 970 shares ResMed common stock sold by director Peter C. Farrell on September 2, 2026

Sale price per share $234.73 per share Reported price for the 970 ResMed common shares sold on September 2, 2026

Shares held after transaction 51,803 shares Direct ownership of ResMed common stock reported for Peter C. Farrell following the sale

Rule 10b5-1 plan adoption date August 12, 2025 Date on which the trading plan governing the reported sale was adopted

Net shares sold 970 shares Net change in buy/sell activity in this filing, all from sales

Key Terms

Rule 10b5-1 plan, open market or private transaction

2 terms

Rule 10b5-1 plan regulatory

"The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

open market or private transaction financial

"Sale in open market or private transaction on September 2, 2026."

FAQ

What insider transaction did RMD director Peter C. Farrell report?

Peter C. Farrell reported selling 970 shares of ResMed common stock on September 2, 2026 at $234.73 per share in an open-market or private transaction, and reported holding 51,803 shares directly after the sale.

Was the recent RMD insider sale by Peter C. Farrell under a Rule 10b5-1 plan?

Yes. The filing states that the sale was conducted under a Rule 10b5-1 plan that was adopted on August 12, 2025, indicating the trades were made pursuant to a pre-arranged trading plan.

How many RMD shares did Peter C. Farrell sell and at what price?

He sold 970 shares of ResMed common stock at a reported price of $234.73 per share on September 2, 2026, in an open-market or private transaction.

How many RMD shares does Peter C. Farrell hold after the reported sale?

After the reported sale, Peter C. Farrell reported direct ownership of 51,803 shares of ResMed common stock. This figure reflects his position immediately following the September 2, 2026 transaction.

What role does Peter C. Farrell hold at RESMED INC (RMD)?

Peter C. Farrell is identified in the filing as a director of RESMED INC. The reported transaction relates to his holdings of ResMed common stock in that capacity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 06:30 AM Accepted by SEC EDGAR 09/04/2026 - 06:30 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FARRELL PETER C

(Last) (First) (Middle)

9001 SPECTRUM CENTER BLVD.

(Street)

SAN DIEGO CALIFORNIA 92123

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	09/02/2026		S(1)		970	D	$234.73	51,803	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025.

	/s/ Peter C. Farrell, Chairman emeritus	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)